Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients

Breast Cancer Research and Treatment

Volumn 148, Issue 1, 2014, Pages 91-98

  Jung, So Youn ^a   Shin, Kyung Hwan ^a   Kim, Myungsoo ^b   Chung, Seung Hyun ^a   Lee, Seeyoun ^a   Kang, Han Sung ^a   Lee, Eun Sook ^a   Kwon, Youngmee ^a   Lee, Keun Seok ^a   Park, In Hae ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Breast cancer; Lymphedema; Neoadjuvant chemotherapy; Taxane

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; INCIDENCE; LYMPH NODE DISSECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SYSTEMIC THERAPY; ADVERSE EFFECTS; AXILLA; BREAST NEOPLASMS; MASTECTOMY; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIOTHERAPY; SURGERY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHEDEMA; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84922004390     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3137-x     Document Type: Article

References (24)

1. Hack TF, Cohen L, Katz J (1999) Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 17(1):143–149
2. Kwan W, Jackson J, Weir LM (2002) Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 20(20):4242–4248
3. Gartner R, Jensen MB, Kronborg L (2010) Self-reported arm-lymphedema and functional impairment after breast cancer treatment–a nationwide study of prevalence and associated factors. Breast 2010 19(6):506–515
4. Petrek JA, Senie RT, Peters M, Rosen pp (2001) Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 92(6):1368–1377
5. Meeske KA, Sullivan-Halley J, Smith AW et al (2009) Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Res Treat 113(2):383–391
6. DiSipio T, Rye S, Newman B, Hayes S (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14(6):500–515
7. Kim M, Kim SW, Lee SU et al (2013) A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy. Int J Radiat Oncol Biol Phys 86(3):498–503
8. Specht MC, Miller CL, Skolny MN et al (2013) Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients. Ann Surg Oncol 20(9):2835–2841
9. Boughey JC, Hoskin TL, Cheville AL et al (2014) Risk factors associated with breast lymphedema. Ann Surg Oncol 21(4):1202–1208
10. Kilbreath SL, Lee MJ, Refshauge KM et al (2013) Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer 21(8):2207–2215
11. Norman SA, Localio AR, Kallan MJ et al (2010) Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 19(11):2734–2746
12. Paskett ED, Naughton MJ, McCoy TP et al (2007) The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev 16(4):775–782
13. Shih YC, Xu Y, Cormier JN et al (2009) Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol 27(12):2007–2014
14. Miller CL, Specht MC, Skolny MN et al (2014) Risk of lymphedema after mastectomy: potential benefit of applying ACOSOG Z0011 protocol to mastectomy patients. Breast Cancer Res Treat 144(1):71–77
15. Warren LE, Miller CL, Horick N et al (2014) The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys 88(3):565–571
16. Qin YY, Li H, Guo XJ et al (2011) Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS ONE 6(11):e26946
17. Bronstad A, Berg A, Reed RK (2004) Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 287(2):H963–H968
18. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381–5387
19. Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29(3):264–271
20. Dominick SA, Madlensky L, Natarajan L, Pierce JP (2013) Risk factors associated with breast cancer-related lymphedema in the WHEL Study. J Cancer Surviv 7(1):115–123
21. Ahmed RL, Schmitz KH, Prizment AE, Folsom AR (2011) Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat 130(3):981–991
22. Sackey H, Magnuson A, Sandelin K et al (2014) Arm lymphoedema after axillary surgery in women with invasive breast cancer. Br J Surg 101(4):390–397
23. Purushotham AD, Bennett Britton TM, Klevesath MB et al (2007) Lymph node status and breast cancer-related lymphedema. Ann Surg 246(1):42–45
24. Coen JJ, Taghian AG, Kachnic LA et al (2003) Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys 55(5):1209–1215